Abstract:Funding source: National Natural Science Foundation of China Award Identifier / Grant number: 82271735 Funding source: Fundamental Research Funds for the Central Universities Funding source: the Key R&D Program of Zhejiang Award Identifier / Grant number: 2022C03167 The authors want to thank Isaac Liu and Andrew Dy for their contribution to the study design. The authors are grateful to all the patients who participated in this study. Research ethics: This study was approved by the Ethics Committee of Children's Hospital, Zhejiang University School of Medicine (2020-IRB-186). Informed consent: Informed consent was obtained from all individuals included in this study, or their legal guardians or wards. Author contributions: The authors have accepted responsibility for the entire content of this manuscript and approved its submission. Competing interests: The authors state no conflict of interest. Research funding: This study was supported by the National Natural Science Foundation of China (82271735), the Key R&D Program of Zhejiang (2022C03167), and the Fundamental Research Funds for the Central Universities. Data availability: The raw data can be obtained on request from the corresponding author. 1. Khalil, M, Teunissen, CE, Otto, M, Piehl, F, Sormani, MP, Gattringer, T, et al.. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577–89. https://doi.org/10.1038/s41582-018-0058-z. Search in Google Scholar PubMed 2. Lunn, MR, Wang, CH. Spinal muscular atrophy. Lancet 2008;371:2120–33. https://doi.org/10.1016/s0140-6736(08)60921-6. Search in Google Scholar 3. Mercuri, E, Darras, BT, Chiriboga, CA, Day, JW, Campbell, C, Connolly, AM, et al.. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med 2018;378:625–35. https://doi.org/10.1056/nejmoa1710504. Search in Google Scholar PubMed 4. Jin, J, Wei, J, Feng, Y, Cui, Y, Zhou, D, Yao, M, et al.. Plasma neurofilament light chain in Chinese children with later-onset spinal muscular atrophy. Clin Chem Lab Med 2022;60:e237–9. https://doi.org/10.1515/cclm-2022-0637. Search in Google Scholar PubMed 5. Nitz, E, Smitka, M, Schallner, J, Akgün, K, Ziemssen, T, von der Hagen, M, et al.. Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. Ann Clin Transl Neurol 2021;8:2013–24. https://doi.org/10.1002/acn3.51449. Search in Google Scholar PubMed PubMed Central 6. Wurster, CD, Steinacker, P, Günther, R, Koch, JC, Lingor, P, Uzelac, Z, et al.. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. J Neurol 2020;267:36–44. https://doi.org/10.1007/s00415-019-09547-y. Search in Google Scholar PubMed 7. Jin, J, Cui, Y, Hong, Y, Zhou, D, He, N, Mao, Z, et al.. Reference values for plasma neurofilament light chain in healthy Chinese children. Clin Chem Lab Med 2021;60:e10–12. https://doi.org/10.1515/cclm-2021-0804. Search in Google Scholar PubMed 8. Wurster, CD, Günther, R, Steinacker, P, Dreyhaupt, J, Wollinsky, K, Uzelac, Z, et al.. Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Ther Adv Neurol Disord 2019;12:1756286419846058. https://doi.org/10.1177/1756286419846058. Search in Google Scholar PubMed PubMed Central © 2024 Walter de Gruyter GmbH, Berlin/Boston

Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients

Neurofilament light chain and profilin‐1 dynamics in 30 spinal muscular atrophy type 3 patients treated with nusinersen

Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective study

Identification of a cytokine profile in serum and cerebrospinal fluid of pediatric and adult spinal muscular atrophy patients and its modulation upon nusinersen treatment

Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy

Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy

The dynamic of changes of pNFH levels in the CSF compared with the motor scales’ scores during three years of nusinersen treatment in children with spinal muscular atrophy types 2 and 3

Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen

Cytokines in cerebrospinal fluid as a prognostic predictor after treatment of nusinersen in SMA patients

Phosphorylated neurofilament heavy chain in cerebrospinal fluid and plasma as a Nusinersen treatment response marker in childhood-onset SMA individuals from Serbia

Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen

Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen

An early Transcriptomic Investigation in Adult Patients with Spinal Muscular Atrophy Under Treatment with Nusinersen

Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?

Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen

Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy

Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients

Study on the efficacy, safety, and biomarkers of nusinersen in type II and III spinal muscular atrophy in children

Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis

Nusinersen treatment in adults with severe spinal muscular atrophy: A real-life retrospective observational cohort study

Value of plasma neurofilament light chain for monitoring efficacy in children with later-onset spinal muscular atrophy under nusinersen treatment